Xtant Medical (NYSEAMERICAN:XTNT) Stock Passes Above 200 Day Moving Average of $0.00

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.99. Xtant Medical shares last traded at $0.93, with a volume of 182,235 shares.

Xtant Medical Stock Down 2.0 %

The company has a current ratio of 2.82, a quick ratio of 1.22 and a debt-to-equity ratio of 0.34.

Hedge Funds Weigh In On Xtant Medical

Several institutional investors have recently added to or reduced their stakes in XTNT. Sterling Investment Advisors Ltd. acquired a new stake in shares of Xtant Medical in the 3rd quarter valued at about $38,000. AWM Investment Company Inc. bought a new stake in shares of Xtant Medical during the third quarter valued at approximately $516,000. AMH Equity Ltd acquired a new position in shares of Xtant Medical during the third quarter worth approximately $653,000. Vanguard Group Inc. lifted its holdings in shares of Xtant Medical by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 1,499,993 shares of the medical device company’s stock worth $1,695,000 after purchasing an additional 14,653 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its position in Xtant Medical by 118.7% in the 4th quarter. Bridgeway Capital Management LLC now owns 368,500 shares of the medical device company’s stock valued at $416,000 after purchasing an additional 200,000 shares during the period. 69.33% of the stock is owned by institutional investors and hedge funds.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix.